---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078077"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:07:06.982784+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics Q2 net loss $16.6M, cuts workforce 75%, explores strategic alternatives

## Summary
- Net loss of $16.6M for Q2 2025 vs $20.4M in Q2 2024; cash and equivalents $18.1M at June 30, 2025.
- R&D expenses $10.5M (down from $17.9M); G&A $1.8M (down from $3.4M); restructuring charge $4.5M.
- Board initiated review of strategic alternatives; engaged Raymond James as financial advisor.
- Workforce reduced ~75% to preserve capital; majority of severance costs in Q3/Q4 2025.
- Updated Phase 2 DeFianCe data showed statistically significant benefit on ORR and PFS in certain CRC subgroups.

## SEC filing metadata
- accession: 0001104659-25-078077
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465925078077/0001104659-25-078077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465925078077/tm2523408d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078077
- JSON: https://secwatch.observer/filing/0001104659-25-078077.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.